Credit Suisse has initiated coverage on AbbVie Inc (NYSE: ABBV) with an Outperform rating and a price target of $170.
AbbVie stands on the edge of best-selling Humira’s U.S. loss of exclusivity (LOE) in 2023. While this remains the focus of investor discussions, Credit Suisse sees it as a catalyst to push the narrative from a value story to a growth story.
According to Credit Suisse analysts, the management has put the building blocks for growth with Skyrizi, Rinvoq, and aesthetics, which are underappreciated.
Related: AbbVie Reports Mixed Earnings, Tightens Guidance, Lifts Quarterly Dividend.
Unlike most peers, there is likely limited urgency for business development (BD), given that no other meaningful LOEs are until 2029. Given its strong cash generation and high dividend yield, low valuation is an attractive entry point as management executes on returning to growth in 2024.
Price Action: ABBV shares are up 1.80% at $154.895 on the last check Friday.
Photo Via Company
Latest Ratings for ABBV
Date | Firm | Action | From | To |
|---|---|---|---|---|
Feb 2022 | UBS | Downgrades | Buy | Neutral |
Feb 2022 | Mizuho | Maintains | Buy | |
Feb 2022 | Barclays | Maintains | Equal-Weight |
View More Analyst Ratings for ABBV
View the Latest Analyst Ratings
See more from Benzinga
Don’t miss real-time alerts on your stocks – join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Source: https://finance.yahoo.com/news/credit-suisse-says-abbvies-humira-193114116.html